BMC cancer · 2025
Expression and prognostic value of MCM2 in type B thymomas.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Du Xin, Cui Jian, Yu Xintao, Cao Dingfang, Zhang Ying, Yu Lei, Li Shanqing
Аннотация
BACKGROUND: Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.
METHODS: mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2's association with prognosis and clinicopathological features.
RESULTS: Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05-0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08-0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.
CONCLUSIONS: MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.
METHODS: mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2's association with prognosis and clinicopathological features.
RESULTS: Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05-0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08-0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.
CONCLUSIONS: MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.